Panntherapi is a pharmaceutical company developing innovative drugs in Neurology. Our goal is to promote higher efficient products and to improve quality of life of patients.
We are first focusing on epilepsy. Epilepsy is the first neurological condition of children, the third of adults, and concerns around 1% of the general population. Epilepsy is defined by recurrent seizures and there are multiple types of epileptic syndromes. Currently around 30% of epileptic patients do not still respond to any anti-seizure drugs and it can grow up to more than 70% in some epileptic syndromes. When it is possible, some patients undergo a surgery to remove the part of the brain involved in the genesis of the seizures, but it fails to be effective in several cases.
Two top notch scientists, both ERC Consolidators and scientists at “Paris Sciences et Lettres” University, got the opportunity to obtain some post-operative brain tissues from epileptic patients. Using this ex vivo tissues, they demonstrated that the tissues continue to have some seizures, allowing to study the pathophysiology of the disease. They identified the interest of a new channel, overexpressed only in pathological tissues, and involved in the genesis of seizures. They demonstrated that blocking this channel allow to fully stop the seizures in more than 80% of the cases using the post operative brain tissues of epileptic patients but also in a representative preclinical model of resistant epilepsy. And the blockage of the channel seems to have no impact on other cognitive functions.
And following the publication of our scientists, the involvement of this channel was demonstrated in the genesis of crisis of other chronic neurological diseases such as multiple sclerosis, pain, etc.
Panntherapi was founded based on this innovation: to develop more efficient and safer drugs for patients.
Our first product is indicated in a highly resistant rare paediatric epilepsy where more than 70% of patients have currently no solution. This indication was identified based on results from ex vivo post-operative brain tissues’ studies where tissues from those patients among others were successfully tested with the identified drug candidate able to block the channels. Panntherapi has developed a long-release paediatric formulation adapted to children from 6 months of age.
The goal of the EIC accelerator program is to support the clinical development of our candidate in epilepsy: first study in healthy volunteer allowing to demonstrate the safety and the long release profile of the product, and then a first study in patients allowing to evaluate the efficient dose and the safety.
We expect to give access of our product to patients first by a compassionate use program in 2027 and to then pursue the development up to final registration and market access. In parallel, Panntherapi is also developing new candidates acting on the same target to be indicated in other chronic neurological diseases with crisis.
